OneChain Immunotherapeutics
Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.
Development of CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies.
OneChain is a biotechnology startup founded in 2020 with a mission to develop CAR-T candidates for the treatment of acute lymphoblastic leukemia and other hematological malignancies. The company, a spin-off from the Josep Carreras Leukemia Research Institute and ICREA, is leveraging the expertise of Dr. Pablo Menéndez to target different antigens as potential treatments for hematological malignancies.
OneChain recently secured a significant milestone in its journey with a €6.70M Seed Round investment on 22 June 2023. The investors in this round included CDTI, Nara Capital, Clave Capital, Invivo Capital Partners, and the Josep Carreras Leukaemia Research Institute.
This funding will likely enable OneChain to further advance its promising CAR-T candidates, marking a pivotal moment in the company's efforts to address unmet medical needs in the field of hematological malignancies. With the backing of reputable investors and a strong foundation rooted in scientific expertise, OneChain is poised to make significant strides in the biotechnology industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €6.70M | 5 |
|
22 Jun 2023 |
| Seed Round | €3.05M | 3 | Invivo Capital Partners, Josep Carreras Leukaemia Research Institute +1 | 27 Jul 2020 |
No recent news or press coverage available for OneChain Immunotherapeutics.
We care about your data, and we'd love to use cookies make your experience better.
